Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection : the STALWART study
| Title: | Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection : the STALWART study |
|---|---|
| Authors: | Tavel J. A.; Babiker A.; Carey C.; Fisher M.; Fox L.; Gey D.; Lopardo G. D.; Lopez J. C.; Markowitz N.; Munroe D.; Paton N.; Ruxrungtham K.; Standridge B.; Wentworth D.; Wyman N.; Aagaard B.; Borup L.; Grarup J.; Jansson P. -O.; Jensen K.; Lundgren J.; Mollerup D.; Reilev S.; Braimah N.; Darbyshire J.; Horton J.; King E.; Smith N.; Van Hooff F.; Cooper D. A.; Courtney-Rodgers D.; Emery S.; Finley E.; Gordin F.; Sanchez A.; Thomas D.; Bebchuk J.; Bollenbeck P.; Denning E.; DuChene A. G.; Fosdick L.; Harrison M.; Krum E.; Larson G.; Neaton J. D.; Nelson R.; Quan K.; Quan S. -F. L.; Schultz T.; Thompson G.; Collins S.; Haerry D. H.; Meulbroek M.; Peavy D.; Rappoport C.; Schwarze S.; Valdez M.; Watson J.; Belloso W. H.; Davey R.; Duprez D.; Gatell J. M.; Hoy J.; Lifson A.; Pederson C.; Perez G.; Price R.; Prineas R.; Rhame F.; Sampson J. H.; Worley J.; Modlin J. F.; Beral V.; Chaisson R. E.; Fleming T. R.; Hill C.; Kim K.; Murray B. E.; Pick B.; Seligmann M.; Weller I.; Luzar M. A.; Martinez A.; Costas V.; Eckstrand J.; Brown S.; Lupo S. H.; Losso M. H.; Anderson J.; Chuah J.; Kelly M.; Orth D.; Wolff M. J.; Rusconi S.; Tambussi G.; Horban A.; Antunes F.; Mansinho K.; Da Conceicao Vera J. A. V.; Himmich H.; Chetchotisakd P.; Kantipong P.; Orkin C.; Portsmouth S.; Winston A.; Wiselka M. J.; Anstead G. M.; Arduino R. C.; Goetz M. B.; Hennessey K.; El-Sadr W.; Labriola A. M.; Nixon D. E.; Rodriguez-Barradas M. C. |
| Contributors: | J.A. Tavel; A. Babiker; C. Carey; M. Fisher; L. Fox; D. Gey; G.D. Lopardo; J.C. Lopez; N. Markowitz; D. Munroe; N. Paton; K. Ruxrungtham; B. Standridge; D. Wentworth; N. Wyman; B. Aagaard; L. Borup; J. Grarup; P.-. Jansson; K. Jensen; J. Lundgren; D. Mollerup; S. Reilev; N. Braimah; J. Darbyshire; J. Horton; E. King; N. Smith; F. Van Hooff; D.A. Cooper; D. Courtney-Rodger; S. Emery; E. Finley; F. Gordin; A. Sanchez; D. Thoma; J. Bebchuk; P. Bollenbeck; E. Denning; A.G. Duchene; L. Fosdick; M. Harrison; E. Krum; G. Larson; J.D. Neaton; R. Nelson; K. Quan; S.-.L. Quan; T. Schultz; G. Thompson; S. Collin; D.H. Haerry; M. Meulbroek; D. Peavy; C. Rappoport; S. Schwarze; M. Valdez; J. Watson; W.H. Belloso; R. Davey; D. Duprez; J.M. Gatell; J. Hoy; A. Lifson; C. Pederson; G. Perez; R. Price; R. Prinea; F. Rhame; J.H. Sampson; J. Worley; J.F. Modlin; V. Beral; R.E. Chaisson; T.R. Fleming; C. Hill; K. Kim; B.E. Murray; B. Pick; M. Seligmann; I. Weller; M.A. Luzar; A. Martinez; V. Costa; J. Eckstrand; S. Brown; S.H. Lupo; M.H. Losso; J. Anderson; J. Chuah; M. Kelly; D. Orth; M.J. Wolff; S. Rusconi; G. Tambussi; A. Horban; F. Antune; K. Mansinho; J.A.V. Da Conceicao Vera; H. Himmich |
| Publisher Information: | Public Library of Science |
| Publication Year: | 2010 |
| Collection: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| Subject Terms: | Adult; Anti-HIV Agent; Atazanavir Sulfate; CD4 Lymphocyte Count; Carbamate; Drug Administration Schedule; Drug Therapy; Combination; Female; Fever; HIV Infection; Human; Interleukin-2; Lopinavir; Male; Nausea; Oligopeptide; Opportunistic Infection; Organophosphate; Pyridine; Pyrimidinone; Ritonavir; Sulfonamide; Treatment Outcome; Settore MED/17 - Malattie Infettive |
| Description: | Background: The Study of Aldesleukin with and without antiretroviral therapy (STALWART) evaluated whether intermittent interleukin-2 (IL-2) alone or with antiretroviral therapy (ART) around IL-2 cycles increased CD4+ counts compared to no therapy. Methodology: Participants not on continuous ART with ≥300 CD4+ cells/mm3 were randomized to: no treatment; IL-2 for 5 consecutive days every 8 weeks for 3 cycles; or the same IL-2 regimen with 10 days of ART administered around each IL-2 cycle. CD4 + counts, HIV RNA, and HIV progression events were collected monthly. Principal Findings: A total of 267 participants were randomized. At week 32, the mean CD4+ count was 134 cells greater in the IL-2 alone group (p |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/20186278; info:eu-repo/semantics/altIdentifier/wos/WOS:000274924000003; volume:5; issue:2; firstpage:1; lastpage:9; numberofpages:9; journal:PLOS ONE; https://hdl.handle.net/2434/699218 |
| DOI: | 10.1371/journal.pone.0009334 |
| Availability: | https://hdl.handle.net/2434/699218; https://doi.org/10.1371/journal.pone.0009334 |
| Rights: | info:eu-repo/semantics/openAccess |
| Accession Number: | edsbas.A7B70687 |
| Database: | BASE |